Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2005 | 2 |
2007 | 1 |
2008 | 1 |
2009 | 1 |
2012 | 1 |
2013 | 1 |
2014 | 1 |
2024 | 0 |
Search Results
7 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
Clinical grade purification and expansion of natural killer cells.
Crit Rev Oncog. 2014;19(1-2):121-32. doi: 10.1615/critrevoncog.2014010931.
Crit Rev Oncog. 2014.
PMID: 24941378
Free PMC article.
Review.
Highly activated and expanded natural killer cells for multiple myeloma immunotherapy.
Garg TK, Szmania SM, Khan JA, Hoering A, Malbrough PA, Moreno-Bost A, Greenway AD, Lingo JD, Li X, Yaccoby S, Suva LJ, Storrie B, Tricot G, Campana D, Shaughnessy JD Jr, Nair BP, Bellamy WT, Epstein J, Barlogie B, van Rhee F.
Garg TK, et al. Among authors: szmania sm.
Haematologica. 2012 Sep;97(9):1348-56. doi: 10.3324/haematol.2011.056747. Epub 2012 Mar 14.
Haematologica. 2012.
PMID: 22419581
Free PMC article.
Item in Clipboard
Interleukin-6 receptor polymorphism is prevalent in HIV-negative Castleman Disease and is associated with increased soluble interleukin-6 receptor levels.
Stone K, Woods E, Szmania SM, Stephens OW, Garg TK, Barlogie B, Shaughnessy JD Jr, Hall B, Reddy M, Hoering A, Hansen E, van Rhee F.
Stone K, et al. Among authors: szmania sm.
PLoS One. 2013;8(1):e54610. doi: 10.1371/journal.pone.0054610. Epub 2013 Jan 23.
PLoS One. 2013.
PMID: 23372742
Free PMC article.
Item in Clipboard
Protein transduction of dendritic cells for NY-ESO-1-based immunotherapy of myeloma.
Batchu RB, Moreno AM, Szmania SM, Bennett G, Spagnoli GC, Ponnazhagan S, Barlogie B, Tricot G, van Rhee F.
Batchu RB, et al. Among authors: szmania sm.
Cancer Res. 2005 Nov 1;65(21):10041-9. doi: 10.1158/0008-5472.CAN-05-1383.
Cancer Res. 2005.
PMID: 16267030
Item in Clipboard
Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma.
van Rhee F, Szmania SM, Dillon M, van Abbema AM, Li X, Stone MK, Garg TK, Shi J, Moreno-Bost AM, Yun R, Balasa B, Ganguly B, Chao D, Rice AG, Zhan F, Shaughnessy JD Jr, Barlogie B, Yaccoby S, Afar DE.
van Rhee F, et al. Among authors: szmania sm.
Mol Cancer Ther. 2009 Sep;8(9):2616-24. doi: 10.1158/1535-7163.MCT-09-0483. Epub 2009 Sep 1.
Mol Cancer Ther. 2009.
PMID: 19723891
Free PMC article.
Clinical Trial.
Item in Clipboard
Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma.
Shi J, Tricot GJ, Garg TK, Malaviarachchi PA, Szmania SM, Kellum RE, Storrie B, Mulder A, Shaughnessy JD Jr, Barlogie B, van Rhee F.
Shi J, et al. Among authors: szmania sm.
Blood. 2008 Feb 1;111(3):1309-17. doi: 10.1182/blood-2007-03-078535. Epub 2007 Oct 18.
Blood. 2008.
PMID: 17947507
Free PMC article.
Item in Clipboard
NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses.
van Rhee F, Szmania SM, Zhan F, Gupta SK, Pomtree M, Lin P, Batchu RB, Moreno A, Spagnoli G, Shaughnessy J, Tricot G.
van Rhee F, et al. Among authors: szmania sm.
Blood. 2005 May 15;105(10):3939-44. doi: 10.1182/blood-2004-09-3707. Epub 2005 Jan 25.
Blood. 2005.
PMID: 15671442
Free PMC article.
Item in Clipboard
Cite
Cite